Search Results - david munn

HOME SEARCH RSS
3 Results Sort By:
Manipulation of the p53 pathway as a novel target for cancer immunotherapy
AU researchers have identified a novel population of immunogenic dendritic cells that arise from rapid transdifferentiation of immature myeloid-derived suppressor ceils (MOSCs) in tumors. We have discovered that this DC trans-differentiation step is driven by p53 expressed by the host (not the tumor). Mice with a deletion of p53 in host cells lose ...
Published: 8/13/2019   |   Inventor(s): David Munn
Keywords(s):  
Category(s): Therapeutics
Fc receptor targeted and virus-like particle (VLP) based tripartite chimeric vaccine technology
TECH ID 2012-025 Title: Tripartitie Polypeptide Vaccine Vector Current State of the Art: Although traditionally viewed as an anti-infectious preventive measure, vaccine use has expanded to treating non-infectious diseases including cancer. Provenge (Dendreon) is currently the only FDA approved therapeutic vaccine at approximately $95,000 per treatm...
Published: 8/13/2019   |   Inventor(s): Yukai He, David Munn, Yuan Hong
Keywords(s):  
Category(s): Therapeutics
Use of Cationic Polymer Polyethylenimine (PEI) to Induce Indoleamine 2,3 Dioxygenase (IDO) as a Means to Control Adaptive Immune Responses
The current invention teaches the systemic treatment with a standard commercial polyethylenimine (PEl) preparation mixed with bacterial plasmid DNA (PEI/pDNA complexes or 'nanoparticles') induced endogenous expression of the enzyme indoleamine 2,3 dioxygenase (IDO) in lungs and lymph nodes (LNs) of treated mice. IDO induction in these tissues was d...
Published: 8/13/2019   |   Inventor(s): Andrew Mellor, David Munn, Lei Huang, Madhav Sharma
Keywords(s):  
Category(s): Therapeutics
© 2019. All Rights Reserved. Powered by Inteum